Sign In
Buy NTRA
$318.35
-3.75 (-1.16%)
At Close: Aug 10, 2026
What to Know About This Natera Insider Transaction as Shares Surge to Record Highs
06:11pm, Monday, 10'th Aug 2026
Moshkevich's non-discretionary sale was executed to cover tax withholding on vesting RSUs under a Rule 10b5-1 plan.
A Natera Co-Founder Sold 2,000 Shares From a Spouse's Account. Here's What It Suggests
06:01pm, Monday, 10'th Aug 2026
This sale was executed under a pre-arranged Rule 10b5-1 trading plan.
Should You Worry That a Natera Co-Founder Sold Shares? Here's What Long-Term Investors Should Know
05:49pm, Monday, 10'th Aug 2026
This sale was non-discretionary and executed under a Rule 10b5-1 plan to cover tax withholding from RSU vesting.
Stanley Druckenmiller's Portfolio Skips Megacap Tech Almost Entirely. Here's What He's Buying Instead.
02:15pm, Saturday, 08'th Aug 2026
Druckenmiller only owns one "Magnificent Seven" stock.
Natera Shares Soar Over 20% To All-Time High, Bolstering Co-Founder's Billionaire Status
05:10pm, Friday, 07'th Aug 2026
40.6%. That is how much Natera shares have grown since the start of the year, when they were priced around the $228 mark. The company's lowest closing price this year occurred in late March, when shar
Natera Q2 Earnings Call Highlights
02:05am, Friday, 07'th Aug 2026
Natera NASDAQ: NTRA reported second-quarter 2026 revenue of approximately $753 million, up about 38% from a year earlier, as record testing volumes and higher average selling prices supported growth a
Natera (NTRA) Reports Q2 Loss, Beats Revenue Estimates
08:13pm, Thursday, 06'th Aug 2026
Natera (NTRA) came out with a quarterly loss of $0.47 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.74 per share a year ago.
Natera, Inc. (NTRA) Q2 2026 Earnings Call Transcript
07:44pm, Thursday, 06'th Aug 2026
Natera, Inc. (NTRA) Q2 2026 Earnings Call Transcript
Natera Reports Second Quarter 2026 Financial Results
04:05pm, Thursday, 06'th Aug 2026
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the second quarter ended June 30, 2026. Rece
Natera Submits Signatera™ to Japan's PMDA for Approval as a Companion Diagnostic in Muscle-Invasive Bladder Cancer
06:00am, Wednesday, 05'th Aug 2026
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it has submitted an application to Japan's Pharmaceuticals an
Cetera Investment Advisers Sells 2,226 Shares of Natera, Inc. $NTRA
03:43am, Wednesday, 05'th Aug 2026
Cetera Investment Advisers lessened its position in shares of Natera, Inc. (NASDAQ: NTRA) by 9.5% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commiss
Stanley Druckenmiller Put 18% of His $3.4 Billion Portfolio in This One Stock. Is Natera a Buy?
11:45am, Tuesday, 04'th Aug 2026
The company has made massive strides in medical diagnostics and is growing at a rapid clip.
Beaconlight Capital LLC Raises Position in Natera, Inc. $NTRA
04:43am, Saturday, 25'th Jul 2026
Beaconlight Capital LLC increased its holdings in shares of Natera, Inc. (NASDAQ: NTRA) by 44.2% in the undefined quarter, according to the company in its most recent filing with the Securities and Ex
Natera, Inc. $NTRA Shares Purchased by Arrowstreet Capital Limited Partnership
04:43am, Saturday, 25'th Jul 2026
Arrowstreet Capital Limited Partnership raised its position in Natera, Inc. (NASDAQ: NTRA) by 1.0% during the undefined quarter, according to its most recent filing with the Securities and Exchange Co
Signatera™ MRD Outperformed AMERK Testing in Predicting Merkel Cell Carcinoma Recurrence in JAMA Dermatology Study
06:00am, Wednesday, 22'nd Jul 2026
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of results from a prospective, multicenter study i
